Pegrizeprument Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Pegrizeprument Growth

• Significant Unmet Need in Solid Organ Transplantation

More than 150,000 solid organ transplants are performed globally each year, and recipients require lifelong immunosuppressive therapy to prevent graft rejection. Current calcineurin inhibitor (CNI)-based regimens, particularly tacrolimus, are highly effective but are associated with nephrotoxicity, metabolic complications, infections, malignancies, and chronic graft dysfunction. Pegrizeprument is being developed to provide effective immunosuppression while potentially reducing long-term toxicities, addressing a major unmet need in transplant medicine.

• Novel CD28-Selective Mechanism Differentiates It from Existing Immunosuppressants

Pegrizeprument selectively blocks CD28-mediated T-cell co-stimulation while preserving CTLA-4 inhibitory signaling, unlike broader co-stimulation inhibitors. This dual mechanism is designed to suppress pathogenic T-cell activation while maintaining physiological immune regulation, potentially improving efficacy and safety. Preclinical non-human primate studies presented at the 2025 World Transplant Congress demonstrated prolonged rejection-free survival and reduced donor-specific antibody formation compared with conventional tacrolimus-based regimens, supporting its differentiated therapeutic profile.

• Expansion Across Multiple Solid Organ Transplant Indications

Although the lead clinical program focuses on kidney transplantation, Veloxis is actively expanding development into liver and heart transplantation. In 2026, the U.S. FDA granted Orphan Drug Designation (ODD) for prevention of organ rejection following both liver transplantation and heart transplantation, broadening the future commercial opportunity beyond kidney recipients. These additional indications increase the potential addressable patient population while leveraging a common immunosuppressive mechanism.

• Regulatory Incentives Reduce Development Risk

The FDA's Orphan Drug Designations for liver and heart transplant rejection provide important development and commercial incentives, including potential market exclusivity following approval, regulatory support, fee reductions, and enhanced interactions with the FDA. These incentives may accelerate development timelines and improve the product's competitive positioning in rare transplant settings.

• Strong Strategic Partnership Supports Global Commercialization

Pegrizeprument was licensed by Veloxis from OSE Immunotherapeutics in 2021, with Veloxis obtaining worldwide rights to develop, manufacture, and commercialize the product for all transplant indications. Veloxis has an established global transplant franchise through products such as Envarsus XR, providing existing commercial infrastructure, transplant-center relationships, and clinical expertise that could facilitate rapid market adoption if pegrizeprument is approved.

Pegrizeprument Recent Developments

In April 2026, the FDA granted Orphan Drug Designation to pegrizeprument for the prevention of heart allograft rejection in heart transplant patients.

“Pegrizeprument Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of Pegrizeprument for potential indication like Transplant rejection in the 7MM. A detailed picture of Pegrizeprument’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Pegrizeprument for potential indications. The Pegrizeprument market report provides insights about Pegrizeprument’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Pegrizeprument performance, future market assessments inclusive of the Pegrizeprument market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Pegrizeprument sales forecasts, along with factors driving its market.

Pegrizeprument Drug Summary

Pegrizeprument (development codes VEL-101 and FR104) is an investigational pegylated, humanized monovalent anti-CD28 monoclonal antibody fragment (Fab) being developed by Veloxis Pharmaceuticals, under license from OSE Immunotherapeutics, for the prevention of acute organ rejection in solid organ transplant recipients. The drug selectively binds to the CD28 co-stimulatory receptor on T cells, blocking CD28-mediated effector T-cell activation while preserving the inhibitory CTLA-4 signaling pathway, thereby providing a more targeted immunomodulatory approach than conventional calcineurin inhibitors. This dual mechanism is designed to suppress alloreactive immune responses while maintaining physiological immune regulation, with the potential to reduce the nephrotoxicity, metabolic complications, and infection risk associated with existing long-term immunosuppressive regimens. Pegrizeprument is administered by intravenous infusion and is being evaluated as a maintenance immunosuppressive therapy for kidney, liver, and heart transplantation. The candidate has received U.S. FDA Orphan Drug Designation for the prevention of organ rejection following both liver and heart transplantation, underscoring its potential to address significant unmet needs in transplant medicine. The report provides Pegrizeprument’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Pegrizeprument Market Report

The report provides insights into:

• A comprehensive product overview including the Pegrizeprument MoA, description, dosage and administration, research and development activities in potential indication like Transplant rejection.
• Elaborated details on Pegrizeprument regulatory milestones and other development activities have been provided in Pegrizeprument market report.
• The report also highlights Pegrizeprument‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Pegrizeprument market report also covers the patents information, generic entry and impact on cost cut.
• The Pegrizeprument market report contains current and forecasted Pegrizeprument sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Pegrizeprument market report also features the SWOT analysis with analyst views for Pegrizeprument in potential indications.

Methodology

The Pegrizeprument market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Pegrizeprument Analytical Perspective

• In-depth Pegrizeprument Market Assessment

This Pegrizeprument sales market forecast report provides a detailed market assessment of Pegrizeprument for potential indication like Transplant rejection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Pegrizeprument sales data uptil 2034.

• Pegrizeprument Clinical Assessment

The Pegrizeprument market report provides the clinical trials information of Pegrizeprument for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Pegrizeprument Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Pegrizeprument Market Potential & Revenue Forecast

• Projected market size for the Pegrizeprument and its key indications
• Estimated Pegrizeprument sales potential (Pegrizeprument peak sales forecasts)
• Pegrizeprument Pricing strategies and reimbursement landscape

Pegrizeprument Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Pegrizeprument Market positioning compared to existing treatments
• Pegrizeprument Strengths & weaknesses relative to competitors

Pegrizeprument Regulatory & Commercial Milestones

• Pegrizeprument Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Pegrizeprument Clinical Differentiation

• Pegrizeprument Efficacy & safety advantages over existing drugs
• Pegrizeprument Unique selling points

Pegrizeprument Market Report Highlights

• In the coming years, the Pegrizeprument market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Pegrizeprument companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Pegrizeprument’s dominance.
• Other emerging products for Transplant rejection are expected to give tough market competition to Pegrizeprument and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Pegrizeprument in potential indications.
• Analyse Pegrizeprument cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Pegrizeprument sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Pegrizeprument in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Pegrizeprument? How strong is Pegrizeprument’s clinical and commercial performance?
• What is Pegrizeprument’s clinical trial status in each individual indications such as Transplant rejection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Pegrizeprument Manufacturers?
• What are the key designations that have been granted to Pegrizeprument for potential indications? How are they going to impact Pegrizeprument’s penetration in various geographies?
• What is the current and forecasted Pegrizeprument market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Pegrizeprument in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Pegrizeprument for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Pegrizeprument? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.